North America Organoids Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenera

North America Organoids Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), and Source (Pluripotent Stem Cells and Organ-specific Adult Stem Cells)

The North America organoids market is expected to grow from US$ 1,357.19 million in 2023 to US$ 3,585.62 million by 2028. It is estimated to record a CAGR of 21.4% from 2023 to 2028.

Growing Adoption of Personalized Drugs Fuels North America Organoids Market

Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to the latest report by the PMC (published in 2021), in the US, the number of personalized medicines in the market has risen from 132 in 2016 to 286 in 2020. The data was shared by tracking the numbers of personalized medicine since 2008 by the PMC.

The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.

Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene-drug association treatment, identification of new therapies, and prediction of patient outcomes.

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors might result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

North America Organoids Market Overview

The North America organoids market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America organoids market. The rising number of patients suffering from chronic conditions and viral diseases, increasing activities in research and development, growing commercialization of organoid models, and surging breakthroughs in stem cell research are the key factors propelling the market for organoids. Also, the growing funding and grants for organoid development are contributing to the growth of the market.

North America Organoids Market Revenue and Forecast to 2028 (US$ Million)

North America Organoids Market Segmentation

The North America organoids market is segmented on the basis of type, application, source, and country.

Based on type, the market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment registered the largest market share in 2023.

Based on application, the North America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest market share in 2023.

Based on source, the North America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger market share in 2023.

Based on country, the North America organoids market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2023.

Corning Inc; Definigen; InSphero; Merck kGaA; Organoid Therapeutics; PeproTech, Inc.; STEMCELL Technologies Inc; and Thermo Fisher Scientific Inc are the leading companies operating in the organoids market in North America.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America organoids market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America organoids market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution